title: Promoter analysis of human glutamate carboxypeptidase II.
abstract: The expression of glutamate carboxypeptidase II (GCP II) is reduced in selective brain regions in schizophrenic patients. To investigate transcriptional mechanisms regulating the human GCP II gene, a 3460 bp DNA fragment comprised of the proximal 3228 bp of 5' untranscribed sequence and first 232 bp of 5' UTR portion of this gene was cloned into the mammalian luciferase reporter gene vector pGL3-Basic. Transfection assays in human astrocyte-derived SVG and human prostate tumor-derived LNCaP cells demonstrated that constructs with 3460, 1590 and 761 bp portions of 5' region of human GCP II gene were able to drive the luciferase reporter gene. Additional deletion constructs showed that in the SVG cell line, constructs with 511 and 411 bp of GCP II gene fragments yielded highest transcriptional activity, with declining activity upon further removal of 5' sequences. 15 bp of the promoter 5' to a 225 bp GCP II fragment were essential for luciferase expression. Thus, in the SVG cells, the proximal 240 bp of the human GCP II promoter (232 bp of the 5' UTR and 8 bp of 5' untranscribed sequences) may represent the core promoter. Further, while a LyF-1 site lies within and overlaps a transcription start site in the 15 bp sequence, site-directed mutagenesis shows that LyF-1 is not the transcription initiator for the "TATA and CAAT" box lacking GCP II gene in the SVG cells. Finally, pattern differences in GCP II gene promoter expression in SVG and LNCaP cells suggest that sequences beyond 240 bp may be important for tissue-specific GCP II expression.
authors: Laboratory of Molecular and Psychiatric Neuroscience, Department of Psychiatry, Harvard Medical School and McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA.
authors: Liqun
authors: L
authors: Han
authors: Dona Lee
authors: DL
authors: Wong
authors: Guochuan
authors: G
authors: Tsai
authors: Zhichun
authors: Z
authors: Jiang
authors: Joseph T
authors: JT
authors: Coyle
mesh_terms: D020121:5' Untranslated Regions; D000954:Antigens, Surface / Q000096:biosynthesis / Q000235:genetics*; D001483:Base Sequence; D015971:Gene Expression Regulation, Enzymologic; D017930:Genes, Reporter; D005822:Genetic Vectors / Q000235:genetics; D043425:Glutamate Carboxypeptidase II / Q000096:biosynthesis / Q000235:genetics*; D006367:HeLa Cells; D006801:Humans; D051740:Ikaros Transcription Factor / Q000235:genetics; D008156:Luciferases / Q000235:genetics; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D010957:Plasmids / Q000235:genetics; D011401:Promoter Regions, Genetic; D012313:RNA / Q000302:isolation & purification; D014158:Transcription, Genetic; D015533:Transcriptional Activation
chemical_list: D020121:5' Untranslated Regions; D000954:Antigens, Surface; C497239:IKZF1 protein, human; D051740:Ikaros Transcription Factor; D012313:RNA; D008156:Luciferases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II
references: J Comp Neurol. 1999 Dec 6;415(1):52-64
references: 10540357
references: Neuropsychopharmacology. 2005 Jan;30(1):7-16
references: 15354184
references: Mamm Genome. 2001 Feb;12(2):117-23
references: 11210180
references: Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51
references: 11296301
references: Genomics. 2001 May 1;73(3):243-54
references: 11350116
references: Gene. 2002 Feb 20;285(1-2):247-56
references: 12039052
references: Gene. 2002 May 29;291(1-2):169-76
references: 12095690
references: Biochim Biophys Acta. 2003 Feb 20;1625(3):246-52
references: 12591611
references: Clin Exp Metastasis. 2004;21(6):495-505
references: 15679047
references: Urology. 2005 Mar;65(3):616-21
references: 15780403
references: Harv Rev Psychiatry. 2005 Jul-Aug;13(4):197-205
references: 16126606
references: Ann N Y Acad Sci. 2006 Sep;1075:235-43
references: 17108217
references: Neurotox Res. 2006 Dec;10(3-4):221-33
references: 17197372
references: Neuroscience. 2007 Feb 23;144(4):1361-72
references: 17150306
references: J Immunol. 2003 Mar 15;170(6):3091-8
references: 12626565
references: Neuropsychopharmacology. 2003 Jul;28(7):1227-34
references: 12700705
references: Neuropsychopharmacology. 2004 Jan;29(1):117-25
references: 14560319
references: Am J Psychiatry. 2004 Sep;161(9):1705-8
references: 15337665
references: Eur J Pharmacol. 1986 Nov 4;130(3):345-7
references: 3539626
references: J Neurochem. 1988 Apr;50(4):1200-9
references: 3346674
references: Brain Res. 1989 Mar 13;482(1):87-96
references: 2706484
references: Mol Cell Biol. 1989 Nov;9(11):4994-5002
references: 2601705
references: Brain Res. 1989 Dec 25;505(1):130-4
references: 2611666
references: Mol Cell Biol. 1991 Oct;11(10):5229-43
references: 1922043
references: J Comp Neurol. 1992 Jan 8;315(2):217-29
references: 1545010
references: Cancer Res. 1993 Jan 15;53(2):227-30
references: 8417812
references: Cancer Res. 1994 Apr 1;54(7):1807-11
references: 7511053
references: Mol Cell Biol. 1994 Nov;14(11):7111-23
references: 7935426
references: Mol Cell Biol. 1994 Dec;14(12):8292-303
references: 7969165
references: Arch Gen Psychiatry. 1995 Oct;52(10):829-36
references: 7575102
references: J Neurosci. 1996 Mar 15;16(6):2034-43
references: 8604048
references: EMBO J. 1996 Oct 1;15(19):5358-69
references: 8895580
references: Immunogenetics. 1997;45(4):266-73
references: 9002447
references: J Neurochem. 1997 Jul;69(1):174-81
references: 9202308
references: Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3215-20
references: 9501243
references: J Biol Chem. 1998 Aug 7;273(32):20417-24
references: 9685395
references: Clin Cancer Res. 1996 Sep;2(9):1445-51
references: 9816319
references: Biochim Biophys Acta. 1998 Nov 26;1443(1-2):113-27
references: 9838072
references: J Cell Biochem. 1999 Sep 1;74(3):395-405
references: 10412041
references: J Neurochem. 2000 Aug;75(2):443-52
references: 10899918